India's cough syrup ban hits Pfizer, Abbott units
Their products are among 344 fixed-dose combination drugs prohibited by regulators
Mumbai
PFIZER Inc and Abbott Laboratories on Monday said they would comply with a ban on a popular cough syrup in India after it was added to a local list of prohibited drugs, sending shares in the US firms' Indian subsidiaries tumbling.
Pfizer's Corex-brand syrup and Abbott's identical Phensedyl contain the narcotic codeine. That brought them to the attention of authorities combating addiction and smuggling, who had been privately pressuring the drugmakers to better police supply chains, Reuters reported last year.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Jim Beam owner bets on canned vodka cocktails to double revenue
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Cordlife served letter of demand, notice of claim from customers
IndoAgri appoints former EDB chairman Philip Yeo as chairman and lead independent director
GSK profit drops 23% in Q1 on higher costs